Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.

Mo Zhang; Johnny Guan; Yun-long Huo; Yong-sheng Song; Li-zhu Chen

Return

Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.

Author: Mo ZHANG ¹ ; Johnny GUAN ² ; Yun-Long HUO ³ ; Yong-Sheng SONG ¹ ; Li-Zhu CHEN ⁴
Author Information

1. Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
2. Department of Urology, University of California, Los Angeles, CA 90095, USA.
3. Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
4. Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Publication Type:Research Support, Non-U.S. Gov't
Keywords: CXCL4L1; prognosis; progression; prostate cancer
MeSH: Adenocarcinoma/surgery*; Aged; Disease Progression; Disease-Free Survival; Down-Regulation; Humans; Male; Middle Aged; Neoplasm Grading; Platelet Factor 4/blood*; Prognosis; Prostate/surgery*; Prostatectomy/methods*; Prostatic Neoplasms/surgery*; Survival Rate
From: Asian Journal of Andrology 2019;21(4):387-392
CountryChina
Language:English
Abstract: Our previous study found that plate factor-4 variant (CXCL4L1) was downregulated in the serum of patients with prostate cancer (PCa). The aim of the present study was to investigate the prognostic value of CXCL4L1 in PCa. In total, 213 PCa patients treated with radical prostatectomy were enrolled and peripheral blood samples of all patients were collected. Expression of serum CXCL4L1 in patients with different tumor stages and grades were measured by enzyme-linked immunosorbent assay (ELISA). The Kaplan-Meier method was applied to estimate the progression to castration-resistant prostate cancer (CRPC), metastasis, biochemical recurrence (BCR)-free survival, and overall survival (OS). Prognostic factors for BCR-free survival and OS were determined by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of CXCL4L1 was significantly lower in PCa patients with advanced pathological tumor stage, high-grade Gleason score, and metastasis. Moreover, downregulation of CXCL4L1 not only strongly correlated with aggressive clinicopathological features, but also predicted tumor progression and unfavorable outcomes. Finally, multivariate Cox regression analyses identified CXCL4L1 as an independent prognostic factor for both BCR-free survival (hazard ratio [HR]: 2.03, 95% confidence interval [CI]: 1.26-3.27; P = 0.004) and OS (HR: 2.26, 95% CI: 1.07-4.79; P = 0.033). In conclusion, our results indicate that CXCL4L1 might serve as a novel and promising prognostic biomarker for patients with PCa and potential therapeutic target in the future.